Alzheimer's disease (AD) is considered a polygenic disorder. This view is clouded, however,
by lingering uncertainty over how to treat the quasi" monogenic" role of apolipoprotein E …

Abstract Apolipoprotein E (Apo-E) is a major cholesterol carrier that supports lipid transport
and injury repair in the brain. APOE polymorphic alleles are the main genetic determinants …

Ten years ago we first proposed the Alzheimer's disease (AD) mitochondrial cascade
hypothesis. This hypothesis maintains that gene inheritance defines an individual's baseline …

Genome-wide association studies (GWAS) have identified several risk variants for late-onset
Alzheimer's disease (LOAD),. These common variants have replicable but small effects on …

Apolipoprotein (apo) E4 is the major genetic risk factor for Alzheimer's disease and is
associated with poor clinical outcome following traumatic brain injury and other …

Abstract The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing,
longitudinal, multicenter study designed to develop clinical, imaging, genetic, and …

Cerebrospinal fluid (CSF) tau, tau phosphorylated at threonine 181 (ptau), and Aβ 42 are
established biomarkers for Alzheimer's disease (AD) and have been used as quantitative …

Abstract The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing,
longitudinal, multicenter study designed to develop clinical, imaging, genetic, and …

Alzheimer's disease (AD) is a complex and heterogeneous neurodegenerative disorder,
classified as either early onset (under 65 years of age), or late onset (over 65 years of age) …

Alzheimer's disease (AD) represents the main form of dementia, and is a major public health
problem. Despite intensive research efforts, current treatments have only marginal …